Introduction: Limited data are available on the epidemiology and predictors of improvement or recovery of left ventricular ejection fraction (LVEF) in outpatients with heart failure (HF) and reduced (≤40%) LVEF (HFrEF). Also, data on the impact of LVEF improvement on outcomes in these patients are scarce. Hypothesis: We hypothesized that (1) clinical characteristics of outpatients with HFrEF can predict improvement of LVEF (to >40%) by 1 year and (2) LVEF improvement (to >40%) leads to lower risk for subsequent events (death and HF admissions). Methods: We evaluated 805 patients with HFrEF who received outpatient care from 01/01/12 to 03/ 31/12 (inception period) and extracted data on serial echocardiographic assessments, interim advanced HF therapies, and outcomes. To assess impact of LVEF trajectory on outcomes, we performed a landmark analysis at 1 year follow-up. Results: Among 724 patients who were alive at 1 year and had not received advanced HF therapies in the interim, 380 (52.5%) had repeat echocardiograms. Of those, 57/380 (15.0%) had improved LVEF to >40% (median change, +18%; 25th to 75th percentile, +10% to +25%), whereas 323 did not improve (0%; -5% to +5%). Table 1 presents the baseline characteristics according to 1-year LVEF change. Baseline LVEF ≥30% (odds ratio [OR] 5.06; 95%CI 2.62-9.77; P < .001), nonischemic HF (OR 2.11; 95%CI 1.11-4.02; P=.023), and absence of implantable cardioverter defibrillator (OR 3.37;; P=.009) predicted LVEF improvement to >40%. In a subset of 272 patients with data on HF duration, improvement was less likely with longer HF duration (OR per year 0.83; 95%CI 0.72-0.94; P=.005). In a landmark analysis at 1 year, 5/57 patients with improved LVEF died in the next 2 years vs. 55/323 among nonimprovers (2-year mortality: 10.1% vs. 17.1%, log-rank P=.13). Improvers had significantly lower rates of combined death or HF admission vs. non-improvers (Fig. 1), hazard ratio 0.37 (95%CI 0.20-0.70; P=.002) in adjusted models. Conclusions:In our chronic HFrEF cohort, 15% of patients improved their LVEF within 1 year. These patients experienced lower rates of combined mortality and HF admission in the next 2 years.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.